Legal/press release/2026-10-13

FTC and States Seek Contempt Ruling Against Martin Shkreli for Alleged Pharma Ban Violation

The Federal Trade Commission, alongside several states, has asked a federal court to hold Martin Shkreli in contempt. They allege Shkreli "flagrantly and repeatedly" violated his lifetime ban from the pharmaceutical industry, specifically by influencing biopharma stocks. This legal action stems from a previous court order that imposed the lifetime ban.

4 articles from 4 outlets covered this story. The underlying claim is sourced from a press release.

What do all outlets agree on?

4 outlets covered “FTC and States Seek Contempt Ruling Against Martin Shkreli for Alleged Pharma Ban…”. All of them report the following:

  • FTC and states are involved in legal action
  • They are asking a federal court to hold Martin Shkreli in contempt
  • The action is for allegedly violating his lifetime ban from the pharmaceutical industry
  • The ban was previously established by a court order

Which outlets covered this?

All 4 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.

What related stories are there?

Get the week in AI in one email

What happened, which outlets reported it, and where their coverage differed. One issue a week.

The first issue hasn’t gone out yet. Subscribe and it’s the one you’ll get.

We’ll send the digest and nothing else. One-click unsubscribe. Privacy.